The present disclosure features chemical entities (e.g., compounds or pharmaceutically acceptable salts and / or hydrates and / or prodrugs of compounds) that produce crosslinks in the
cornea in response to
exposure to
electromagnetic radiation. The present disclosure also features compositions comprising the chemical entities and other methods of using and preparing the same. The chemical entities can be used, for example, to treat a subject (e.g., a human) suffering from a
disease, disorder, or condition in which an abnormal shape of the
cornea (e.g., corneal
thinning, e.g., bilateral corneal
thinning, e.g., bilateral
thinning of the central, paracentral, or
peripheral cornea; or corneal steepening (e.g., bulging)) causes the
pathology and / or symptoms and / or progression of the
disease, disorder, or condition. Non-limiting examples of such diseases, disorders, or conditions include: (i) corneal ectatic diseases; (ii) vision conditions; (iii) diseases, disorders, or conditions that are sequelae of or coexist with any of the above or any of the diseases, disorders, or conditions described herein. More specific non-limiting examples of such diseases, disorders or conditions include
keratoconus, corneal
sphericity, pellucid marginal degeneration, corneal ectasia (e.g., post-operative ectasia, such as post-
LASIK ectasia), Terrien marginal degeneration, myopia, hyperopia,
astigmatism, irregular
astigmatism and
presbyopia.